Abstract 1864P
Background
Globally, more than 1.3 mio adolescents and young adults (AYAs) are diagnosed with cancer each year. Long-term survival has increased due to improved cancer therapy; however, a potential side effect is reduced fertility. Despite development in fertility preservation uncertainty regarding future fertility is still of major concern to the AYAs. The aim of this study was to identify to what extent nulliparous, female AYAs with cancer have children after cancer treatment compared to nulliparous female AYAs without cancer.
Methods
This is a national register study based on the Danish National Assisted Reproductive Technology-Couple cohort including female AYAs diagnosed with cancer when aged 18-39 from 1978–2016. According to diagnosis onset, the female AYAs with cancer were randomly age-matched with 60 female AYAs without cancer (comparison group: CG). Study participants were followed until end of study, death, or migration (31/12-2017). Death was incorporated as a competing risk in all analyses. Hazard Ratio (HR) were calculated, comparing the female AYAs with cancer with the CG. HR was adjusted for time of diagnosis, immigration status, marital status, and educational level.
Results
33.3% of AYAs with cancer had at least one child after cancer treatment vs. 40% in the CG. Female AYAs with malignant melanoma had solely a higher HR of having children after cancer treatment compared to the CG. Female AYAs with leukaemia, breast and CNS cancer had the lowest HR of having children after cancer treatment, especially in the age interval 32-39 years. Table: 1864P
N (%) | ≥ 1 child after cancer N (%) | Adjusted HR (95% CI)* | |||
18-25 y | 26-31 y | 32-39 y | |||
All | 7519 (100) | 2505 (33.3) | 0.77 (0.72-0.82) | 0.65 (0.61-0.69) | 0.59 (0.52-0.67) |
Gyn cancer | 1773 (23.6) | 435 (24.5) | 0.49 (0.42-0.58) | 0.44 (0.38-0.50) | 0.39 (0.29-0.52) |
Breast cancer | 1115 (14.8) | 179 (16.1) | 0.63 (0.42-0.95) | 0.46 (0.37-0.56) | 0.35 (0.26-0.48) |
Mal melanoma | 1960 (26.1) | 1071 (54.6) | 1.02 (0.93-1.12) | 1.03 (0.93-1.13) | 1.13 (0.92-1.39) |
CNS cancer | 303 (4.0) | 65 (21.5) | 0.70 (0.51-0.97) | 0.40 (0.26-0.61) | 0.25 (0.06-0.97) |
Leukaemia | 258 (3.4) | 37 (14.3) | 0.39 (0.26-0.57) | 0.25 (0.09-0.65) | 0.41 (0.13-1.26) |
Lymphoma | 278 (3.7) | 78 (28.1) | 0.63 (0.47-0.85) | 0.48 (0.30-0.75) | 0.76 (0.32-1.84) |
CG | 499,616 | 199,861 (40.0) | 1 | 1 | 1 |
*Adjusted analysis is based on complete case sample, N=6275. Approximately 16% (6275/7519) is excluded in the adjusted analysis due to missing data.
Conclusions
A third of nulliparous, female AYAs with cancer had at least one child after cancer which is lower than for female AYAs without cancer. The HR for having children after cancer decrease with increased age being lowest in female AYAs with leukaemia, breast- and CNS cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1604P - A comparative study of symptom prevalence between adults and elderly patients with advanced cancer diagnosis under palliative care: A single institution experience
Presenter: Hodan Abdullah
Session: Poster session 05
1605P - The impact of cancer pain on survival of lung cancer patients receiving immune checkpoint inhibitors
Presenter: Sichao Wang
Session: Poster session 05
1606P - Sarcopenia, depression, and modes of feeding among cancer patients
Presenter: Muhammad Khokhar
Session: Poster session 05
1607P - Patient perceptions of the efficacy, safety, and quality of the evidence available on medicinal cannabis: A survey of Australian cancer patients - comparing users to non-users
Presenter: Joseph Taylor
Session: Poster session 05
1608P - Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Presenter: Omer Dizdar
Session: Poster session 05
1609P - A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
Presenter: Eun Hee Jung
Session: Poster session 05
1610P - A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project
Presenter: Pablo Flores Paco
Session: Poster session 05
1611P - Family carers’ experiences with brain metastases: A longitudinal qualitative study
Presenter: Tonje Lundeby
Session: Poster session 05
1612P - Demonstrating the complexity of need and the effectiveness of integrated palliative care: An analysis of routinely collected patient centred outcome measures
Presenter: Joanne Hayes
Session: Poster session 05
1613P - The BreakThrough cancer malnutrition
Presenter: Stefano De Santis
Session: Poster session 05